HLN - HALEON - Share Chat

Haleon plc is a leading global consumer healthcare company, spun out from GSK plc in July 2022 and subsequently listed on the London Stock Exchange (LSE) as a FTSE 100 constituent, with an American Deprivation Receipt (ADR) listing on the NYSE. The demerger also incorporated Pfizer’s former consumer health joint venture.

Operating across five key categories – Oral Health, Pain Relief, Respiratory, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS) – Haleon boasts a robust portfolio of well-known, market-leading brands including Sensodyne, Panadol, Advil, Centrum, Otrivin, and Theraflu. Its defensive business model, characterised by stable demand for essential health products and strong brand equity, underpins resilient revenues and cash flow generation. The company focuses on organic growth through innovation and market penetration in both developed and emerging markets.